Disc Medicine (IRON) announced the appointment of Steve Caffe, MD as the company’s Chief Regulatory Officer, CRO. Dr. Caffe is an experienced biotech executive with significant expertise in global regulatory leadership across a wide range of therapeutic areas, including hematology, oncology, and rare diseases. Most recently, Caffe served as Head of Regulatory Affairs at CRISPR Therapeutics (CRSP) where he was involved in the development and approval of Casgevy for sickle cell disease and beta thalassemia.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRON:
- Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer
- Disc Medicine to Participate in Upcoming Investor Conferences
- TJX downgraded, Crocs upgraded: Wall Street’s top analyst calls
- Disc Medicine initiated with an Overweight at Wells Fargo
- Disc Medicine files automatic mixed securities shelf